Horizon Technology Finance Corporation Stock News

FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon” or “HRZN”) (the “Company”), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital and private equity backed and publicly traded companies in the technology, life science, healthcare information and services, ...

I am increasingly cautious on BDCs due to rising non-accruals, weaker earnings, and looser underwriting amid intense competition for private credit deals. Elevated interest rates are suppressing BDC valuations and making it harder for borrowers to service debt, leading to fewer quality investment opportunities. Dividend coverage is weakening across many BDCs, with higher non-accruals and PIK in...

FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon” or “HRZN”) (the “Company”), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital and private equity backed and publicly traded companies in the technology, life science, healthcare information and services, ...

The current macro backdrop is restrictive for strong BDC sector performance. An important implication of this unfavorable environment is that many BDCs will have to sooner or later synchronize their dividend yields to portfolio asset yields (which have decreased quite a bit). In my view, we will see more and more BDC dividend cuts being announced this year.

We take a look at the action in business development companies through the first week of May and highlight some of the key themes we are watching. BDCs fell around 1.5% this week due to a couple of weak Q1 reports, with the sector still below pre-Liberation Day levels. Despite recent dips, historically resilient BDCs are showing strong ROE figures, suggesting selective opportunities for patient...

Horizon Technology Finance's earnings continue to decline, with a 37.6% price drop over the last year, leading to a potential HRZN dividend cut in 2025. The BDC's concentrated portfolio in healthcare technology and high non-accruals weaken its ability to generate positive growth in a high interest rate environment. HRZN's NAV has consistently declined, and net investment income fails to cover d...

BDCs are inherently a risky asset class. It does not make sense to go further up in the risk curve here. One of such, in my view, illogical moves is investing in VC-focused BDCs.

Investors love dividend stocks, especially those with ultra-high yields, because they offer a significant income stream and have substantial total return potential.